4Sakai Y,Hayakawa T,Kondo T,et al.Protective effects of a prostaglandin E1 oligomer on taurocholate-induced rat pancreatitis[J].J Gastroentol Hepatol,1992,7(6):591-5.
5Pozar J,Berger Z,Simon K,et al.Biphasic effect of prostaglandin E1 on the severity of pancreatitis induced by a closed duodenal loop in rats[J].Pancreas,1996,12:159-64.
6Yamanaka K,Saluja A K,Brown G E,et al.Protective effects of prostaglandin E1 on acute lung injury of caerulein-induced acute pancreatitis in rats[J].Am J Physiol,1997,272(1 pt 1):G23-30.
9Takahashi H,Imamura M,Mikami Y,et al.Exacerbation of acute pancreatitis in the presence of chronic liver injury in rats,with special reference to therapeutic efficacy of prostaglandin E1[J].Pancreas,1999,19(2):199-204.
10Hirano T,Hirano K.Thromboxane A2 receptor antagonist prevents pancreatic microvascular leakage in rats with caerulein-induced acute pancreatitis[J].Int J Surg Investig,1999,1(3):203-10.
8Formela LJ, Galloway SW, Kingsnorth AN, et al. Inflammatory mediators in acute pancreatitis[ J ]. British Journal of Surgery, 1995, 82 (1):6-13.
9Norman J. The role of cytokine in the pathogenesis of acute pancreatitis [J] .Am J Surg, 1998, 175(1):76-83.
10Niederau C, Schonberg M. New developments in the pathophysiology of inflammatory pancreatic disease[J]. Hepatogastroenterology, 1999, 46(29): 2722-2728.
3Toouli J,Brooke-Smith M,Bassi C,et al.Guidelines for the management of acute pancreatitis[J].J Gastroenter Hepat,2002,17(suppl):S15-S39.
4Ferreira FL,Bota DP,Bross A,et al.Serial evaluation of the SOFA score to predict outcome in critically ill patients[J].JAMA,2001,286(14):1754-1758.
5Vincent JL,de Mendonca A,Cantraine F,et al.Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units:results of a multicentric,prospective study[J].Crit Care Med,1998,26:1793-1800.
8Wu JX, Yuan YZ, Xu JY, et al. Changes in somatostatin receptor ex2pression of the pancreas and effectiveness of octreotide in rats with acute necrotizng pancreatitis [ J ]. Chin J Dig Dis ,2004,5 ( 1 ) :35-39.
